Cibus

General Information
Business:

 

We are a biotechnology company using advanced technologies to develop desirable plant traits for the global seed industry. Founded in 2001, we have developed and are commercializing a proprietary and highly differentiated gene-editing technology, which we refer to as the Rapid Trait Development System. RTDS enables us to efficiently introduce customizable, specific and predictable value-enhancing traits into plants and microorganisms. This ability to precisely edit plant genes without the integration of foreign genetic material, or recombinant DNA, establishes our technology as truly non-transgenic, both in process and product, and distinguishes us from competitors.

Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Employees: 134
Founded: 2001
Contact Information
Address 6455 Nancy Ridge Drive, San Diego, CA 92121, US
Phone Number +1 (858) 450-0008
Web Address http://www.cibus.com
View Prospectus: Cibus
Financial Information
Market Cap $350.0mil
Revenues $2.77 mil (last 12 months)
Net Income $-39.5 mil (last 12 months)
IPO Profile
Symbol CBUS
Exchange NASDAQ
Shares (millions): 6.7
Price range $14.00 - $16.00
Est. $ Volume $100.0 mil
Manager / Joint Managers Morgan Stanley/ BofA Merrill Lynch/ Piper Jaffray
CO-Managers -
Expected To Trade: 2/14/2019
Status: Withdrawn
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change